Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Deferred Revenue: 2022-2025

Historic Current Deferred Revenue for Dianthus Therapeutics (DNTH) over the last 2 years, with Sep 2025 value amounting to $954,000.

  • Dianthus Therapeutics' Current Deferred Revenue rose 854.00% to $954,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $954,000, marking a year-over-year increase of 854.00%. This contributed to the annual value of $479,000 for FY2024, which is N/A change from last year.
  • Latest data reveals that Dianthus Therapeutics reported Current Deferred Revenue of $954,000 as of Q3 2025, which was up 99.16% from $479,000 recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Current Deferred Revenue peaked at $954,000 during Q3 2025, and registered a low of $100,000 during Q4 2022.
  • Its 3-year average for Current Deferred Revenue is $348,875, with a median of $289,500 in 2023.
  • Data for Dianthus Therapeutics' Current Deferred Revenue shows a peak YoY skyrocketed of 854.00% (in 2025) over the last 5 years.
  • Dianthus Therapeutics' Current Deferred Revenue (Quarterly) stood at $100,000 in 2022, then reached $100,000 in 2023, then remained steady at $479,000 in 2024, then skyrocketed by 854.00% to $954,000 in 2025.
  • Its Current Deferred Revenue stands at $954,000 for Q3 2025, versus $479,000 for Q2 2025 and $479,000 for Q1 2025.